Author reply to VA-MENGOC-BC cross-protection (2018HV0022)
نویسندگان
چکیده
منابع مشابه
author reply
dear editor: thank you for your letter ref. no 2003-2 dated 7 november 2010 regarding the comments of an ophthalmologist from thailand named professor viroj wiwan on my article titled “evaluation of contrast sensitivity, color vision and visual acuity in patients with and without diabetes”. he has suggested that the combination of existing tests may be a good way to increase the sensitivity of ...
متن کاملletter to the editor: author reply
dear editor: we thank dr asadi amoli for her interest in our article. 1 dr asadi amoli pointed out that specific and sensitive rhabdomyosarcoma (rms) markers should be investigated in our case. 2 we agree with dr asadi amoli ’s opinion and are sorry that the results of pathology examination and myogenin (myf-4) staining studied in a local hospital were not provided in our case report. an ex...
متن کاملauthor's reply
it is a great pleasure to receive two valuable comments about our article regarding sudden cardiac death (scd) in young athletes from two well known experts working in the field of preparticipation evaluation and prevention of sports injuries. we, as authors, generally agree with both authors' comments. however, some considerations should be re-emphasized here. .....
متن کاملReply from the author.
and reliability mandates extra capacity, fail-safes, and standard operating procedures, but especially attention to the team. Engineering also embraces ‘cognitive ergonomics’ to maximize mental processes (awareness, perception, reasoning) and expedite individualized responses. ‘Teamwork’ provides a useful prism through which to examine cognitive workload, decision making, reliability (vs safety...
متن کاملCuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application.
This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC®) obtained by the Finlay Institute in Havana, Cuba. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningococcal disease caused by serogroup B meningococcus; it is also effective against serogroup C. VA-M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Vaccines & Immunotherapeutics
سال: 2018
ISSN: 2164-5515,2164-554X
DOI: 10.1080/21645515.2018.1448335